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What you need to know
• Cannabis based products for medicinal use contain cannabinoids derived
from the cannabis plant, including ∆9-tetrahydrocannabinol (THC),
cannabidiol (CBD), or a combination of THC and CBD. Synthetic
cannabinoids for medicinal use typically mimic the effects of specific
cannabinoids such as THC
• THC is the constituent of cannabis that causes the “high,” whereas CBD
is not intoxicating at typical doses. THC and CBD have contrasting
mechanisms of action and therapeutic indications; THC carries a higher
risk of adverse events compared with CBD
• Rescheduling on 1 November 2018 permits some unlicensed cannabis
based products to be prescribed for the first time in the UK, but only by
doctors on the relevant Specialist Register of the General Medical
Council
• Indications for treatment, supported by evidence of low to moderate
certainty, include chronic pain, some treatment resistant epilepsies, and
nausea and vomiting caused by chemotherapy (table 2)
• Non-medicinal CBD products are legal and widely available on the
internet and from health food retailers, but they lack quality standards
and should not be used for medicinal purposes
Until recently, cannabis and its derivatives were widely
restricted under legislation which stated they had no medical
value and carried a substantial risk of misuse. Policy is rapidly
changing, and cannabis can now be prescribed for medicinal
use in many countries, including the UK. This provides
important new opportunities for treating patients although these
need to be weighed up against potential risks. Several different
medicinal products exist, with contrasting mechanisms of action,
efficacy, and safety. Use of these products may increase as new
evidence arises and policy changes occur. Here we review this
emerging field.
What are the latest developments in
regulation, in the UK and internationally?
In the UK, drugs perceived by policy makers to have no medical
value and a high risk of misuse, such as MDMA
(3,4-methylenedioxy-methamphetamine, common street name
“ecstasy”) are placed in Schedule 1 of the Misuse of Drugs
Regulations 2001. These drugs cannot be prescribed, and
research can only be conducted under a Home Office licence.
On 1 November 2018, unlicensed cannabis based products were
moved from Schedule 1 to Schedule 2 in the UK, enabling them
to be prescribed for the first time.1 This amendment of UK
legislation affected some but not all products, as some were
already listed in Schedule 2 or 4 (table 1). Non-medicinal
synthetic cannabinoids (which are found in products such as
“Spice”) were not rescheduled and remain in Schedule 1.
Cannabidiol (CBD) has minimal risk of misuse5 and was never
scheduled in the UK.
At the time of writing, in the US cannabis is available for
medicinal use in 33 US states and for non-medicinal use in 10
US states, although both remain illegal under federal law. Other
recent developments include the legalisation of cannabis for
non-medicinal use in Canada on 17 October 2018. The World
Health Organization has proposed that cannabis should be
rescheduled within international law because of growing
evidence of its medicinal applications.6
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What types of product are available and
where?
The cannabis plant can produce at least 144 naturally occurring
compounds known as cannabinoids.7 The most widely
researched cannabinoids are ∆9-tetrahydrocannabinol (THC)
and CBD. THC is the primary constituent of cannabis that causes
the “high” whereas CBD is not intoxicating at typical doses.
Several different products exist for medicinal use and these
differ in THC/CBD profile, formulation, licensed indications,
and conditions for prescribing (table 1). See the glossary of
terms (box 1) for accepted definitions.
Box 1: Key terms
• Cannabinoid—a drug that acts on the endocannabinoid system. The
cannabis plant synthesises many cannabinoids such as THC and CBD
• THC—∆9-tetrahydrocannabinol, a cannabinoid used for medicinal
purposes and non-medicinally for its intoxicating effects
• CBD—cannabidiol, a cannabinoid with contrasting mechanisms of action
and therapeutic indications to THC. Not intoxicating at typical doses
• Cannabis based products for medicinal use—medicinal products
containing cannabis or cannabinoids derived from the cannabis plant
(eg, THC and/or CBD)
• Synthetic cannabinoids for medicinal use—medicinal products
containing synthetically produced cannabinoids which typically mimic
the effects of THC
• Non-medicinal CBD products—products containing CBD that are
widely sold as herbal remedies but are not regulated as medicinal
products
• Non-medicinal cannabis—material from the cannabis plant that is not
regulated as a medicinal product, widely used for its intoxicating effects
• Non-medicinal synthetic cannabinoids—synthetic cannabinoids that
are not structurally related to naturally occurring cannabinoids and are
not currently recognised for medicinal use (eg, synthetic cannabinoid
receptor agonists, which are found in products such as “Spice”)
Cannabis based products for medicinal use
Cannabis based products that were previously listed in Schedule
1 can now be prescribed by doctors on the General Medical
Council Specialist Register in the UK, on a named patient basis.
Currently, general practitioners in the UK cannot prescribe them.
These products are not licensed for specific medical indications
but are used off licence for medicinal purposes in many
countries, and are certified for quality according to good
manufacturing practice. Examples include herbal cannabis (floral
material from the cannabis plant). The recommended route of
administration is through a medical vapouriser device9 and
smoking is currently prohibited under NHS guidance.10 Extracts
from the cannabis plant (such as cannabis oils containing THC)
are also available for oral administration.
Some cannabis based products were already available for
medicinal use before rescheduling in 2018. Sativex, an oral
spray derived from the cannabis plant containing THC and CBD
in a 1:1 ratio, is licensed for the treatment of spasticity in
multiple sclerosis in 29 countries, including the UK, Israel,
Canada, Brazil, and Australia. However, meta-analysis suggests
its effectiveness may be limited11 and it is not recommended by
the UK’s National Institute for Health and Care Excellence
(NICE) because of poor cost effectiveness.12 Epidiolex, an oral
CBD solution derived from the cannabis plant, was licensed by
the US Food and Drug Administration in June 2018 for the
treatment of seizures in two rare and severe forms of childhood
epilepsy—Lennox-Gastaut syndrome and Dravet syndrome. At
the time of writing, an application for the same indication is
under review by the European Medicines Agency, and it can
currently be prescribed on a named patient basis in the UK.
Synthetic cannabinoids for medicinal use
Dronabinol and nabilone are synthetically produced medicinal
products that mimic the effects of THC. Dronabinol has an
identical structure to THC, while nabilone has a related structure
and is more potent than dronabinol, requiring lower doses to
achieve clinical efficacy. Countries including the US, the
Netherlands, Germany, Austria, and Croatia have licensed the
use of both products. They are licensed for the treatment of
weight loss in patients with AIDS and of nausea and vomiting
in people receiving chemotherapy who have failed to respond
adequately to conventional anti-emetics. Nabilone is licensed
in the UK while dronabinol is not licensed but can be prescribed
on a named patient basis.
Non-medicinal products
CBD products are also widely available in health food shops
and on the internet in the UK and elsewhere (fig 1) and are not
scheduled or regulated as medicines. Their THC or psychoactive
content is legally controlled not to exceed 0.2% in the EU.8 As
with other herbal remedies, the declared contents of
non-medicinal CBD preparations is variable, and often
inaccurate,2 13 and these products sometimes exceed the legal
limit of THC.13 Moreover, the amount of CBD in these products
is typically far lower14 15 than in clinical trials16 (eg, 25 mg in a
non-medicinal product versus 150-1500 mg/day in clinical
trials). Advise patients that these widely available CBD products
lack quality assurance and should not be treated as medicines.
Other products include non-medicinal cannabis and
non-medicinal synthetic cannabinoids, which are both currently
illegal in the UK.
Why and how are cannabis based
products and cannabinoids therapeutic
(or harmful)?
THC and CBD have contrasting mechanisms of action on the
endocannabinoid system,17 18 which is widely expressed in the
mammalian central and peripheral nervous systems. These
actions may account for their therapeutic effects. For example,
CBD increased plasma endocannabinoid levels in a clinical trial
in schizophrenia, which correlated with the degree of symptom
improvement.19 When taken together with THC, CBD may offset
some of the adverse effects of THC, such as memory impairment
and paranoia.20 21 Therefore, the balance of THC and CBD may
contribute to safety as well as therapeutic effects. CBD has an
excellent safety profile and is well tolerated, even at high doses.22
THC carries an increased risk of adverse events (including
serious adverse events). In a systematic review and
meta-analysis, cannabinoids (primarily THC) were associated
with a fivefold increase in rates of disorientation and dizziness,
compared with placebo or active comparators.11
What is the evidence underpinning
medicinal use of cannabis based products
and cannabinoids?
Table 2 summarises evidence from systematic reviews of
cannabis based products and cannabinoids for the treatment of
chronic pain, multiple sclerosis, treatment resistant epilepsy,
and nausea and vomiting associated with chemotherapy.11 23 24
There is less available evidence to estimate the effectiveness of
these products for other indications, such as appetite and weight
loss associated with HIV/AIDS, Tourette syndrome, anxiety,
post-traumatic stress disorder, and schizophrenia.11 26 27
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The limited number of randomised trials for unlicensed cannabis
based products is partly attributable to the regulatory challenges
of conducting research on drugs in Schedule 1.28 Removing
these barriers is an important benefit of rescheduling, which
should lead to a stronger evidence base to guide clinical decision
making. At the time of writing, the UK National Institute for
Health Research (NIHR) has pledged dedicated funding and
has called for grant proposals to investigate cannabis based
products for medicinal use.
Limitations of current evidence include the inappropriate
handling of withdrawals from treatment, selective reporting of
outcomes, and inadequate descriptions of randomisation,
allocation concealment, and blinding.11 Heterogeneity in the
types of product tested, including differences in
pharmacokinetics and the balance of THC and CBD content,
makes it difficult to establish optimal therapeutic formulations
and dosing regimens. More larger and rigorous clinical trials
are needed, including further exploration of dose-response and
interactions with other medicines.27 For example, both nabilone
(THC) and epidiolex (CBD) may increase the effects of central
nervous system depressants such as alcohol.29 30 Epidiolex is
metabolised by cytochrome P450 enzymes and may increase
the risk of adverse effects from other medicines metabolised by
this pathway, such as clobazam and valproate.29
How should doctors manage requests for
cannabis based products and
cannabinoids? (box 2)
Box 2: Managing requests for cannabis based products and
cannabinoids
Consider
Is this indication supported by evidence from randomised clinical trials?
(table 2)
What is the cannabinoid profile of the medicinal product being requested
(THC, CBD, THC+CBD?)
Is this medicinal product available, and who can prescribe it? (table 1)
Might this medicinal product interact with other prescribed drugs?
Are specific considerations necessary for young people, children and
babies, older people, people with mental health problems, people with a
learning disability, pregnant women, and women who are breastfeeding?
If a prescription is not offered, might this patient seek or use a
non-medicinal product lacking safety and quality assurance?
Guidelines are currently being prepared by NICE, which will
initially focus on the indications listed in table 2. Interim
guidance from England’s Chief Medical Officer states that
unlicensed cannabis based products can only be prescribed by
doctors on the General Medical Council Specialist Register.10
The same guidance also stipulates that doctors should prescribe
products only for disorders within their specialty; when there
is clear published evidence or UK guidelines to support
treatment; when clinical need cannot be met by a licensed
medicine; and when established treatment options have been
exhausted. Additional guidance has been provided by the Royal
College of General Practitioners31 and NHS England.32
Within this framework, specialists in the UK will need
authorisation from their medical director and agreement from
the multidisciplinary team, using existing protocols on controlled
drugs. Therefore, use of unlicensed cannabis based products in
the UK may be limited initially, even in specialist settings.
Active, compassionate, and fully informed engagement with
patients requesting treatment remains important, and questions
to consider are given in box 2. As this is a rapidly evolving field,
seek confirmation from the relevant statutory authorities before
changing practice.
Education into practice
To what extent might it be stigmatising for a patient to request and use a
cannabis based product, and how can this be managed?
Are patients fully aware of the difference between medicinal and
non-medicinal products, their legal status, and the risk of harm or
prosecution associated with them?
How can I record and share information from my practice on requests for,
uses of, and responses to cannabis based products to ensure that future
regulations and guidance better meet the needs of patients?
How this article was created
We used the most up to date and relevant information available to us from
systematic reviews, meta-analyses, and key clinical trials. Summary statistics
and grading of evidence were obtained from systematic reviews for indications
included in forthcoming NICE guidelines. We referred to NICE, the Department
for Health & Social Care, NHS England, the UK Home Office, and the Advisory
Council for the Misuse of Drugs (ACMD). We discussed our article with
clinicians, researchers, and patients.
How patients were involved in the creation of this article
We discussed our article with patients who had health conditions for which
there is evidence that cannabis based products or cannabinoids may be
effective. We conducted interviews with them asking what they thought would
be helpful for patients and clinicians to learn from this article. We showed
them drafts of this article and invited them to provide feedback which was
incorporated into subsequent versions of the article. On the basis of this
feedback, we adapted the structure of the article such that recent policy
developments were presented first. We expanded our discussion of the
differences between medicinal products and health food supplements, and
added a new table to provide an accessible overview of these different
products. We highlighted that some patients may seek unlicensed or illegal
products if they are unavailable on prescription, and that requesting cannabis
based products from a doctor and using them could be stigmatising.
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⨁⨁⨁◯ ModerateOdds ratio: 1.46 (1.16 to 1.84).
More effective than placebo
30% reduction in painPlaceboSativex (THC+CBD)9 (1734)Chronic pain23
⨁⨁⨁◯ ModerateWeighted mean difference:
−0.12 (−0.24 to 0.01).
Not more effective than placebo
Ashworth spasticity
scale




1.74 (1.24 to 2.43).
More effective than placebo
50% reduction in
seizure frequency




Odds ratio: 3.82 (1.55 to 9.42).
More effective than placebo
Complete response in
nausea and vomiting
PlaceboDronabinol (THC)3 (102)Nausea and vomiting
due to
chemotherapy11
Grading of recommendations, assessment, development, and evaluations (GRADE)25
⨁⨁⨁⨁ High, the authors have a lot of confidence that the true effect is similar to the estimated effect
⨁⨁⨁◯ Moderate, the authors believe that the true effect is probably close to the estimated effect
⨁⨁◯◯ Low, the true effect might be markedly different from the estimated effect
⨁◯◯◯ Very low, the true effect is probably markedly different from the estimated effect
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Figure
Fig 1 Non medicinal CBD products are widely available
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